Ronald George
Rheumatology · Wilmington, NCNPI 1265657894
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 1,196 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 33 manufacturers reported payments, led by Amgen at 36.4% of the total.
Across 1,196 payments — averaging $15.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$7K
- AbbVie$2K
- UCB, Inc.$2K
- Pfizer$2K
- Johnson & Johnson$740
- GSK$686
- plus $4K from 27 others
Across 269 payments — averaging $3756.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$381K
- Sun Pharmaceutical Industries Inc.$263K
- Eli Lilly$251K
- AbbVie$96K
- E.r. Squibb & Sons, L.L.C.$13K
- Gilead$5K
- plus $1K from 1 others
What the payments were for
- Speaking & faculty fees$240%
- Food & beverage$18,86699%
- Education$1081%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 380 | $6,917 |
| AbbVie | 147 | $2,390 |
| UCB, Inc. | 128 | $2,000 |
| Pfizer | 210 | $1,821 |
| Johnson & Johnson(2 entities) | 46 | $740 |
| GSK | 41 | $686 |
| Lilly USA, LLC | 38 | $605 |
| AstraZeneca(2 entities) | 33 | $605 |
| Novartis | 27 | $538 |
| Genentech USA, Inc. | 27 | $372 |
| Radius Health, Inc. | 13 | $278 |
| Fresenius Kabi USA, LLC | 11 | $274 |
| E.r. Squibb & Sons, L.L.C. | 12 | $217 |
| Aurinia Pharma U.S., Inc. | 9 | $153 |
| Mallinckrodt Hospital Products Inc. | 7 | $142 |
| Regeneron Healthcare Solutions, Inc. | 13 | $136 |
| Bristol Myers Squibb | 6 | $127 |
| Sobi, Inc | 5 | $126 |
| Sanofi-aventis U.S. LLC | 2 | $107 |
| Antares Pharma, Inc. | 6 | $105 |
| Boehringer Ingelheim | 5 | $103 |
| Sanofi | 5 | $98 |
| Organon | 4 | $88 |
| Mallinckrodt Enterprises LLC | 3 | $81 |
| Medexus Pharma, Inc. | 4 | $49 |
| Hikma Pharmaceuticals USA | 3 | $45 |
| Lundbeck LLC | 2 | $45 |
| Sandoz | 2 | $39 |
| Arbor Pharmaceuticals, Inc. | 2 | $32 |
| Pharmacosmos Therapeutics Inc. | 1 | $24 |
| Acorda Therapeutics, Inc | 2 | $24 |
| Grifols USA, LLC | 1 | $19 |
| Neurelis, Inc. | 1 | $12 |
How this compares
$18,999 in reported general payments places this provider in the 85th percentile of 210 rheumatology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 257 | $1,835,685 |
| Skyrizi PenRisankizumab-Rzaa | 62 | $1,275,738 |
| Enbrel SureclickEtanercept | 155 | $1,148,124 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 123 | $994,455 |
| RinvoqUpadacitinib | 107 | $770,885 |
| Cosentyx Sensoready PenSecukinumab | 75 | $595,272 |
| Xeljanz XrTofacitinib Citrate | 96 | $591,413 |
| SimponiGolimumab | 49 | $295,423 |
| Orencia ClickjectAbatacept | 49 | $284,420 |
| TremfyaGuselkumab | 18 | $276,460 |
| OtezlaApremilast | 49 | $275,129 |
| EnbrelEtanercept | 34 | $238,271 |
| KevzaraSarilumab | 35 | $163,106 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 11 | $146,465 |
| Cimzia (2 Pack)Certolizumab Pegol | 19 | $110,247 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $2,390 | $770,885107 claims |
| Johnson & JohnsonSimponi, Tremfya, Remicade | $740 | $661,51180 claims |
| AmgenOtezla, Enbrel | $6,917 | $513,40083 claims |
| SanofiKevzara | $98 | $163,10635 claims |
| UCB, Inc.Cimzia (2 Pack) | $2,000 | $110,24719 claims |
| GSKBenlysta | $686 | $58,11012 claims |
| Lilly USA, LLCOlumiant | $605 | $54,11514 claims |
| Hikma Pharmaceuticals USAMitigare | $45 | $3,97517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 210 rheumatology providers in North Carolina.
Other rheumatology in Wilmington
- Wendy SimmonsWilmington$462K
- Mark HarrisWilmington$22K
- Heather FavoritoWilmington$9K
- Gordon LamCharlotte$2.7M
- Ralph SnydermanDurham$1.3M
- Andrew LasterCharlotte$421K
- Ana RossRaleigh$417K
- Gwenesta MeltonFayetteville$410K
- Joseph ShanahanDurham$407K
- Jill ZouzoulasCharlotte$377K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.